6MAY - 2023EditorialStacey Smith Editor-in-Chiefeditor@pharmatechoutlook.comContract Research Organizations (CROs) and pharmaceutical companies will remain indispensable partners in the healthcare industry for years. CROs have revolutionized drug development, enabling pharmaceutical, biotechnology, and medical device companies to bring life-saving therapies to patients efficiently. In recent years, the United States has witnessed remarkable growth in the field of (CROs) in providing a wide range of research and development services to support the clinical trial process and advance healthcare innovations. They collaborate with pharmaceutical and biotech companies to conduct clinical trials, partner with various sectors, create employment opportunities and adhere to regulations set by regulatory authorities. These services enable efficient and effective execution of clinical trials, helping companies bring new drugs to market. CROs in the US are responsible for ensuring clinical trials are conducted in compliance with GCP guidelines, protecting the rights and safety of study participants, and generating high-quality data for regulatory submissions. They leverage emerging technologies to enhance the efficiency and quality of clinical trials, contribute to drug development, and address healthcare challenges. Through their expertise, expertise, and adherence to regulatory standards, they contribute significantly to the successful execution of clinical trials and research studies.In this edition of Pharma Tech Outlook, we present top CROs in the United States that are at the forefront of driving innovation and helping companies ensure that drugs are developed safely and effectively. Featured company Melior Discovery is a pioneer of in vivo phenotypic screening and a leader in the area of drug repositioning. The company's platform enables rapid and cost-effective identification of new therapeutic potential by systematically screening candidates in a diverse array of validated in vivo disease models. The magazine also includes insightful opinions of Brian Thoma, Director Service Solutions, QIAGEN; Robert Lambert, Director of Manufacturing Technical Services, Noven Pharmaceuticals, and Tony Street, Vice President for Clinical Trial Supplies, Orifarm. Their extensive experience in managing clinical trials ensures compliance with regulatory standards and good clinical practices, mitigating potential risks and ensuring high-quality data collection.We hope these valuable insights from industry leaders featured in this edition will assist you in making informed decisions for your businesses.Let us know your thoughts.CRO: Unlocking the Potential of Clinical Research to Drive Medical AdvancementsCopyright © 2023 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.MAY - 2023, Vol 09 - Issue 03 (ISSN 2644-2787) Published by ValleyMedia, Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com Disclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsEditor-in-ChiefStacey SmithVisualizerHenry SmithEditorial StaffAaron Pierce Ava GarciaJenna VegasCarolynn Walters Justin SmithPaul Barbersales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.comEmail:Parley Meadow
< Page 5 | Page 7 >